Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich protein 4 (PRR4) is a member of the proline-rich protein family predominantly expressed in human lacrimal, submucosal, and salivary glands[1][2][3][4][5]. It lacks a conserved repetitive domain found in other proline-rich proteins[4]. PRR4 plays a role in protecting mucosal surfaces of the eye and oral cavity, likely by binding bacterial pathogens and plant tannins, and by inhibiting calcium phosphate precipitation. It is a major component of saliva and tears. Reduced expression of PRR4 has been observed in conditions such as dry eye syndrome, diabetic retinopathy, thyroid-associated orbitopathy, and several cancers including laryngeal and nasopharyngeal carcinoma, suggesting a role as a protective or suppressive molecule in epithelial inflammation and malignancy[1][2][3][4][5]. There is currently no evidence that PRR4 itself is a direct therapeutic target, receptor, enzyme, or a protein with characterized drug-binding or receptor-like properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline-rich protein 4 (PRR4).